- Drug: Dupixent (dupilumab)
- Manufacturer: Sanofi | Regeneron
Route of Administration: Subcutaneous
Site of Care: Outpatient
Approved Indication:
-
- treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
- add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma
- add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps
- treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kilograms, with eosinophilic esophagitis
- treatment of adult patients with prurigo nodularis
- add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease and an eosinophilic phenotype
- treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment
-
- Disease: asthma, atopic dermatitis, chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyp, chronic spontaneous urticaria, eosinophilic esophagitis, prurigo nodularis
- Therapeutic Area: Gastroenterology, Rheumatology, Dermatology
- Enrollment Form Link: www.dupixent.com/patient-support
- Phone Number: 1-844-387-4936
- Fax Number: 1-844-387-9370
- Product Website: dupixent.com